These ASX 200 blue chip shares could rise 25% to 40%

Analysts are bullish on these big names. Let's see what they are recommending.

Key points
  • Cochlear, a leader in hearing devices, is recommended by UBS due to its dominant market share and growth potential, with a projected 30% upside as it continues to innovate and expand product offerings.
  • CSL, despite recent pressures from its Seqirus spin-off and regulatory concerns, remains a strong investment due to its robust demand and strategic investments in plasma collection and therapy development, with Morgans forecasting a nearly 40% rise.
  • REA Group, dominating Australia's online property advertising, is expanding into financial services and data products, with Bell Potter suggesting a 25% upside, benefiting from potential interest rate cuts and its strategic market positioning.

Blue chip shares are often the cornerstone of long-term portfolios. They offer stability, strong market positions, and the ability to grow earnings through multiple economic cycles.

And with recent volatility pulling several high-quality names down meaningfully, analysts see buying opportunities emerging across the ASX 200.

For example, here are three ASX 200 blue chip shares that brokers have flagged as top buys right now. They are as follows:

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

Cochlear Ltd (ASX: COH)

Cochlear could be an ASX 200 blue chip share to buy. It is a leader in implantable hearing devices globally. Demand for its products continues to rise as ageing populations grow and access to hearing treatments expands worldwide.

The company's ongoing investment in research and new product development has helped it maintain its dominant market share and support steady revenue growth. And with a strong balance sheet, rising volumes, and a history of delivering consistent earnings and dividends, Cochlear continues to stand out as a reliable long-term compounder.

UBS is a fan of the company and has a buy rating and a $350.00 price target on the stock. This implies around 30% upside from current levels.

CSL Ltd (ASX: CSL)

Global biotech heavyweight CSL has come under pressure in recent months, with investor sentiment dampened by the planned Seqirus spin-off, regulatory uncertainty, and a slower-than-hoped recovery in plasma margins. But despite recent share price weakness, CSL's long-term fundamentals remain strong.

CSL continues to invest in expanding its plasma collection network, developing new therapies, and strengthening its manufacturing footprint in the United States. Demand for its core plasma-derived products remains robust, and analysts expect earnings momentum to rebuild as temporary headwinds ease.

So, with its shares trading close to a 52-week low, CSL's valuation looks significantly more appealing than it has in years.

Morgans sees meaningful upside from current levels. It has a buy rating and a $249.51 price target on its shares, which suggests that they could rise almost 40%.

REA Group Ltd (ASX: REA)

Finally, REA Group could be an ASX 200 blue chip share to buy now. It dominates Australia's online property advertising market, supported by powerful pricing power, strong customer relationships, and significant digital scale.

It has also expanded beyond listings into financial services, data products, and international investments, broadening its growth runway. With more interest rate cuts potentially coming in 2026, the company's premium positioning and deep integration into the property ecosystem give it substantial leverage to any improvement in listing volumes.

Bell Potter remains bullish. It has a buy rating and $244.00 price target on its shares, implying nearly 25% upside from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough Thursday for investors this session.

Read more »

A player kicks a soccer ball to score a goal while players from both teams watch on.
Broker Notes

6 ASX 200 shares scoring renewed buy calls this week

Brokers retained a positive view on Zip, IAG, BHP, and other shares this week. 

Read more »

A shadow bear faces a man against the backdrop of a falling share price.
ASX Share Market News

ASX 200 slides as investors head for the exits. Is there more pain to come?

The benchmark is struggling as several major companies trade lower.

Read more »

Two people tired and resting after sports race.
Broker Notes

Which ASX shares just got downgraded by brokers?

Brokers reduced their ratings on Resolute Mining, Elders, New Hope and other stocks this week. 

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Echo IQ, Bluescope Steel, Lovisa shares

Here are some new expert recommendations on three ASX stocks.

Read more »

Couple using their digital tablet together.
Broker Notes

Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares

Three experts share their views on three ASX 200 shares.

Read more »

Woman and man at work looking at data on a tablet at work.
Opinions

Buy, hold, sell: BHP, CSL, and Westpac shares

I take a closer look at how I would approach these three major ASX shares today.

Read more »

Boys making faces and flexing.
Broker Notes

Buy, hold, sell: Telstra, AGL, PLS shares

Brokers give their latest verdicts on these ASX shares.

Read more »